Why Tempus AI Skyrocketed This Week

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the development of Merck and Moderna's cancer vaccine.

The Motley Fool • 2 hours ago

Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know

The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million. The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.

The Motley Fool • Aug 22, 2026

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

The transaction involved 48,842 shares with an estimated value of about $2.7 million. This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.

The Motley Fool • Aug 22, 2026

Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.

The transaction involved 41,095 shares executed at a weighted average price of $49.61 per share, representing a total value of $2.0 million. The sale was non-discretionary, executed to cover tax obligations associated with the vesting of restricted stock units, and does not reflect the insider's view on the stock.

The Motley Fool • Aug 22, 2026

Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened

The transactions involved 17,314 shares at a weighted average price of $53.71 per share, totaling $930,000. The sales were executed directly by Schoenherr and were primarily structured to satisfy tax withholding obligations.

The Motley Fool • Aug 22, 2026

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know

These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

The Motley Fool • Aug 22, 2026

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

The Motley Fool • Aug 22, 2026

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.

The Motley Fool • Aug 22, 2026

Tempus AI: Winning With Precision Medicine

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.

Seeking Alpha • a day ago

Tempus AI Stock Climbs Friday: What's Driving the Move?

Tempus AI Inc. (NASDAQ:TEM) shares are trading higher on Friday as traders continue to digest the latest follow-through from this week's Merck–Moderna clinical-trial headline.

Benzinga • Aug 21, 2026